Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 5, 2018New BD Survey Conducted by HIMSS Analytics® Reveals Heightened Need for Seamless Integration of Disparate Technologies during Medication Transit
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will demonstrate its comprehensive approach to integrated, enterprise medication management to help...
-
Feb 20, 2018CE-IVD labeled PAXgene® Blood ccfDNA tube will be available in Western Europe
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial availability of the CE-IVD marked PAXgene(®) Blood ccfDNA tube within...
-
Feb 13, 2018The BD Onclarity(TM) HPV Assay can detect 14 high-risk HPV types and provide additional information to guide physician decision-making
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pre-market approval from the U.S. Food and Drug Administration...
-
Feb 6, 2018
Click on the links below to view results for the 2018 first fiscal quarter: View document online PDF file of BD 2018 first fiscal quarter results About BD BD is one of the largest global medical...
-
Feb 6, 2018- As reported, revenues of $3.080 billion increased 5.4 percent, or 3.7 percent on a currency-neutral basis, which includes an estimated 110 basis point adverse impact from the previously disclosed change in the U.S. dispensing business model.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.080 billion for the first fiscal quarter ended December 31,...